The statistics of phase 0 trials
- 20 April 2010
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 29 (10) , 1072-1076
Abstract
The PD‐driven phase 0 trial is a new form, designed to be a first‐in‐man study, often of a new agent, conducted to assess drug effect on a molecular target, by means of a pharmacodynamic (PD) assay, in a very small number (10–15) of patients. Such a study is meant to be a proof of principle trial to determine whether the agent yields the PD effect predicted by pre‐clinical studies. The dosage is meant to be pharmacologically active, but is neither toxic nor likely to yield clinical benefit. Such a trial may be used to serve as a very early test of an agent's biologic effect, allowing for early weeding out of ineffective agents, or as an early means of determining the most promising of competing analogue agents. This manuscript will present designs for such PD‐driven studies that are statistically efficient and rigorous, focusing on non‐comparative trials. The phase 0 trial promises to become an increasingly important tool for facilitating and speeding the development of new therapeutic agents, particularly in oncology. Copyright © 2010 John Wiley & Sons, Ltd.Keywords
This publication has 9 references indexed in Scilit:
- Phase 0 trials: a platform for drug development?The Lancet, 2009
- Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced MalignanciesJournal of Clinical Oncology, 2009
- Phase 0 Clinical Trials: An Answer to Drug Development Stagnation?Journal of Clinical Oncology, 2009
- Designing Phase 0 Cancer Clinical TrialsClinical Cancer Research, 2008
- Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical PracticeMolecular Interventions, 2007
- Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 2007
- Early Average Change in Tumor Size in a Phase 2 Trial: Efficient Endpoint or False Promise?JNCI: Journal of the National Cancer Institute, 2007
- Compressing drug development timelines in oncology using phase '0' trialsNature Reviews Cancer, 2007
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989